Development of treatments for Down syndrome.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Neuronal oscillations in cognition: Down syndrome as a model of mouse to human translation.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2025
   Review
2. Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
   Review
3. Indicators of health in Down syndrome: A virtual focus group study with patients and their parents.Journal of applied research in intellectual disabilities : JARID · 2023
   Article
4. Research attitudes in families of individuals with Down syndrome: importance for clinical trials.Alzheimer's research & therapy · 2022
   Article

Corrections and comments

• Comment on
  Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.2022

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as